Fishing around for the undervalued.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BLEG This acquisition comes at a great time as Branded Legacy has recently signed several large white label manufacturing deals, ensuring throughput and creating a clear path to profitability.
$BCDS share structure: Authorized Shares
680,000,000
02/28/2024
Outstanding Shares
285,278,272
02/28/2024
Restricted
265,009,844
02/28/2024
Unrestricted
20,268,428
02/28/2024
Held at DTC
20,260,662
02/28/2024
Float
20,260,662
12/19/2023
https://www.otcmarkets.com/stock/BCDS/security
$BCDS
Phase III approaching product pipeline: https://respirerx.com/product-pipeline/
$RSPI
$BLEG news: Branded Legacy, Inc. Strengthens Position in BioTech Industry with Letter of Intent to Purchase Sycamore BioPharma, LLC
PR Newswire
MELBOURNE, Fla., Feb. 29, 2024
The Company will secure over 2 Million in assets as well as personnel necessary for clinical trials in upcoming acquisition
https://www.otcmarkets.com/stock/BLEG/news/Branded-Legacy-Inc-Strengthens-Position-in-BioTech-Industry-with-Letter-of-Intent-to-Purchase-Sycamore-BioPharma-LLC?id=431952
Sycamore BioPharma brings state-of-the-art extraction equipment to the table, further bolstering Branded Legacy's already robust extraction capabilities. This combined technological prowess will fuel advancements in product development, ensuring the delivery of superior, research-backed remedies that set new standards in the biotech industry. "We are thrilled to welcome Sycamore BioPharma into the Branded Legacy family. This strategic acquisition will greatly enhance our existing technological infrastructure The addition of their high volume Critical CO2 extraction capabilities to our existing CO2 capacity is a crucial step in securing a major Kavalactone extraction and refinement contract. In turn we will employ our recently acquired topical and cosmetic packaging equipment as a huge cost saving measure to Sycamore BioPharm's operations. Together, our combined capabilities propel us to the forefront of innovation, ensuring the delivery of high-quality, scientifically-backed solutions that set new standards in the biotech industry." Said Joseph Holladay, Branded Legacy COO.
$BLEG
Website: https://sycamorebp.com/
$BLEG
$BLEG news: Branded Legacy, Inc. Strengthens Position in BioTech Industry with Letter of Intent to Purchase Sycamore BioPharma, LLC
PR Newswire
MELBOURNE, Fla., Feb. 29, 2024
The Company will secure over 2 Million in assets as well as personnel necessary for clinical trials in upcoming acquisition
https://www.otcmarkets.com/stock/BLEG/news/Branded-Legacy-Inc-Strengthens-Position-in-BioTech-Industry-with-Letter-of-Intent-to-Purchase-Sycamore-BioPharma-LLC?id=431952
$BLEG news: Branded Legacy, Inc. Strengthens Position in BioTech Industry with Letter of Intent to Purchase Sycamore BioPharma, LLC
https://www.otcmarkets.com/stock/BLEG/news/Branded-Legacy-Inc-Strengthens-Position-in-BioTech-Industry-with-Letter-of-Intent-to-Purchase-Sycamore-BioPharma-LLC?id=431952
$BLEG Upcoming Product Releases:
VapeRx Plus Kava Anti Anxiety Rescue, VapeRx Plus Kava Sleep, and VapeRx Plus Kava Pain Management: Soon to be launched, these vapable CBD plus Kava products aim to enhance the anti-anxiety effects, promote restful sleep, and manage pain effectively.
ElixRx Plus Kava Anti Anxiety, ElixRx Plus Kava Sleep, and ElixRx Plus Kava Pain Management: Expected to be available shortly, these ElixRx Plus Kava products will offer a comprehensive and sustained approach to anti-anxiety, sleep aid, and pain management.
Branded Legacy remains at the forefront of the industry, continually pushing the boundaries of CBD and botanical-based products. With a focus on quality, safety, and efficacy, the company strives to make a positive impact on its customers, employees, and shareholders. In a proactive move to strengthen the company's financial position and enhance shareholder value, Branded Legacy, Inc. recently negotiated the purchase of outstanding debt of $1,500,000 at a remarkable price of $450,000. This strategic decision not only eliminates a substantial liability but also safeguards against any potential conversion of the debt into shares. With a commitment to fiscal responsibility, a relentless pursuit of useful alkaloids, and a dedicated product development team, stay tuned for the continued release of many outstanding products.
$RSPI KRM-II-81, a GABAA receptor potentiator, is being developed to provide pain relief without the harmful side effects commonly associated with opioids.
Meanwhile, the NIH HEAL Initiative is a comprehensive response to the opioid crisis launched in April 2018, aiming to improve prevention, treatment, and pain management strategies.
“We are excited to see the robust anti-pain efficacy of KRM-II-81, knowing the urgent need for non-opioid pain therapeutics. We continue to be impressed by the comparative ‘therapeutic index’ of this compound that we had predicted from earlier research,” said Dr Jeffrey Witkin, a senior research fellow with RespireRx.
As well as pain relief, KRM-II-81 has shown promising results in treatment-resistant epilepsy models and human translational studies, thereby positioning it as a versatile candidate for addressing a range of neurological disorders.
$RSPI KRM-II-81, a GABAA receptor potentiator, is being developed to provide pain relief without the harmful side effects commonly associated with opioids.
Meanwhile, the NIH HEAL Initiative is a comprehensive response to the opioid crisis launched in April 2018, aiming to improve prevention, treatment, and pain management strategies.
“We are excited to see the robust anti-pain efficacy of KRM-II-81, knowing the urgent need for non-opioid pain therapeutics. We continue to be impressed by the comparative ‘therapeutic index’ of this compound that we had predicted from earlier research,” said Dr Jeffrey Witkin, a senior research fellow with RespireRx.
As well as pain relief, KRM-II-81 has shown promising results in treatment-resistant epilepsy models and human translational studies, thereby positioning it as a versatile candidate for addressing a range of neurological disorders.
$BLEG Upcoming Product Releases:
VapeRx Plus Kava Anti Anxiety Rescue, VapeRx Plus Kava Sleep, and VapeRx Plus Kava Pain Management: Soon to be launched, these vapable CBD plus Kava products aim to enhance the anti-anxiety effects, promote restful sleep, and manage pain effectively.
ElixRx Plus Kava Anti Anxiety, ElixRx Plus Kava Sleep, and ElixRx Plus Kava Pain Management: Expected to be available shortly, these ElixRx Plus Kava products will offer a comprehensive and sustained approach to anti-anxiety, sleep aid, and pain management.
Branded Legacy remains at the forefront of the industry, continually pushing the boundaries of CBD and botanical-based products. With a focus on quality, safety, and efficacy, the company strives to make a positive impact on its customers, employees, and shareholders. In a proactive move to strengthen the company's financial position and enhance shareholder value, Branded Legacy, Inc. recently negotiated the purchase of outstanding debt of $1,500,000 at a remarkable price of $450,000. This strategic decision not only eliminates a substantial liability but also safeguards against any potential conversion of the debt into shares. With a commitment to fiscal responsibility, a relentless pursuit of useful alkaloids, and a dedicated product development team, stay tuned for the continued release of many outstanding products.
Good morning, 50dma at .0013, 200dma at .0016, RSI at 41.08 on daily chart.
$RSPI
Good morning, short week last week, perfect recipe for news.
$BLEG
RespireRx's key asset moves to next stage of NIH initiative
RespireRx's key asset moves to next stage of NIH initiative
Proactive Investors
Published Feb 13, 2024 09:20
Updated Feb 13, 2024 10:15
RespireRx's key asset moves to next stage of NIH initiative
Proactive Investors - RespireRx Pharmaceuticals (OTC:RSPI) Inc, a pioneer in the field of neuronal signaling treatments, said its lead compound, KRM-II-81, has progressed to the next evaluation phase of the National Institutes for Health's HEAL Initiative's Preclinical Screening Platform for Pain (PSPP) program.
In doing so the compound demonstrated efficacy in reducing pain-like behaviors in rat models, covering both male and female subjects across various pain measures, underlining its potential to treat acute, chronic, and neuropathic pain without leading to tolerance or sedation.
KRM-II-81, a GABAA receptor potentiator, is being developed to provide pain relief without the harmful side effects commonly associated with opioids.
Meanwhile, the NIH HEAL Initiative is a comprehensive response to the opioid crisis launched in April 2018, aiming to improve prevention, treatment, and pain management strategies.
“We are excited to see the robust anti-pain efficacy of KRM-II-81, knowing the urgent need for non-opioid pain therapeutics. We continue to be impressed by the comparative ‘therapeutic index’ of this compound that we had predicted from earlier research,” said Dr Jeffrey Witkin, a senior research fellow with RespireRx.
As well as pain relief, KRM-II-81 has shown promising results in treatment-resistant epilepsy models and human translational studies, thereby positioning it as a versatile candidate for addressing a range of neurological disorders.
https://m.ca.investing.com/news/stock-market-news/respirerxs-key-asset-moves-to-next-stage-of-nih-initiative-3262753
$RSPI
$BCDS Unrestricted 20,268,428 as of 02/22/2024
Setting bids, way to add till she takes off IMO
$RSPI
Good morning all
$RSPI
Good morning all, looking forward to updates soon.
$BLEG
$IDVV .0007:
https://t.co/ChAgr8WTTC
— International Endeavors Corp (@IDVVcorp) February 21, 2024
Corporate update issued today for $idvv #ai #SportsGambling #fantasy #UFC #NFL #NBA #MLS
https://t.co/ChAgr8WTTC
— International Endeavors Corp (@IDVVcorp) February 21, 2024
Corporate update issued today for $idvv #ai #SportsGambling #fantasy #UFC #NFL #NBA #MLS
Loving the opportunities
$BLEG
$BLEG nice SS: Authorized Shares
900,000,000
01/22/2024
Outstanding Shares
512,913,066
01/11/2024
Restricted
112,847,209
01/11/2024
Unrestricted
400,065,857
01/11/2024
Held at DTC
400,042,389
01/11/2024
acquired licenses, property, and machinery and now beginning to use it. Looking forward to contracts ahead.
$BLEG .0015x.0016 rolling out new products: https://www.thealcannabist.com/shop/vaperx-headache-and-migraine-rescue-formula/
$BLEG rolling out products: https://www.thealcannabist.com/shop/vaperx-headache-and-migraine-rescue-formula/
$BLEG rolling out products: https://www.thealcannabist.com/shop/vaperx-headache-and-migraine-rescue-formula/
$BLEG Products starting: https://www.thealcannabist.com/shop/vaperx-headache-and-migraine-rescue-formula/
$BLEG
https://t.co/EV5xEdpgCI$BLEG Another REAL otc company! Oh, and they just did a share reduction. Looking forward to trying and sharing these products, ESPECIALLY the Anxiety Rescue Formula. I have used other cbd products in the past, not in vape form, but I will definitely be… pic.twitter.com/A87pqvUMsy
— Buffalo Fireside Chats (@buffalofireside) February 17, 2024
$BLEG
Explore our story and growing product line at https://t.co/t2pwAQtoXJ🌿✨ #TheAlcannabist #MigraineSolution #CBD $BLEG #BLEGsubsidiary
— Branded Legacy, Inc. $BLEG (@BrandedLegacy) February 19, 2024
Explore our story and growing product line at https://t.co/t2pwAQtoXJ🌿✨ #TheAlcannabist #MigraineSolution #CBD $BLEG #BLEGsubsidiary
— Branded Legacy, Inc. $BLEG (@BrandedLegacy) February 19, 2024
GM all 3 day weekend ahead
$RSPI
GM all 3 day weekend ahead
$BLEG
Great opps IMO. Always quiet until peeps load on bids.
$RSPI
Company has set themselves up for progress ahead, they have accomplished many things over the past couple months. She will move easy now with news. Next steps $$$$ IMO
$BLEG
$BCDS low SS reminds me of the old days: https://www.otcmarkets.com/stock/BCDS/security
Good morning all.
Next phase in our growth is the contracts $$
$BLEG
Light volume, but accumulation picking up, looks like seller is out.
$IDVV
$RSPI product pipeline: https://respirerx.com/product-pipeline/
$RSPI
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders: https://pubmed.ncbi.nlm.nih.gov/35041859/
$RSPI